LAVA Therapeutics N.V. (LVTX)

NASDAQ: LVTX · IEX Real-Time Price · USD
3.130
-0.210 (-6.29%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-6.29%
Market Cap 82.28M
Revenue (ttm) 7.52M
Net Income (ttm) -46.64M
Shares Out 26.29M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 150,713
Open 3.320
Previous Close 3.340
Day's Range 3.050 - 3.390
52-Week Range 1.131 - 6.470
Beta 0.63
Analysts Strong Buy
Price Target 6.00 (+91.69%)
Earnings Date Jun 6, 2024

About LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candida... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 25, 2021
Employees 37
Stock Exchange NASDAQ
Ticker Symbol LVTX
Full Company Profile

Financial Performance

In 2023, LVTX's revenue was 6.77 million, a decrease of -65.09% compared to the previous year's 19.39 million. Losses were -41.97 million, 31.6% more than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for LVTX stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 91.69% from the latest price.

Price Target
$6.0
(91.69% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developi...

24 days ago - GlobeNewsWire

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023 Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023

5 weeks ago - GlobeNewsWire

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study...

2 months ago - GlobeNewsWire

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gamma...

5 months ago - GlobeNewsWire

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platf...

7 months ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gam...

8 months ago - GlobeNewsWire

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody ® plat...

8 months ago - GlobeNewsWire

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

• LAVA-1207 for the treatment of prostate cancer will continue as the lead program • LAVA-051 Phase 1/2a clinical trial will be discontinued • Associated cost savings and initiatives are expected to e...

10 months ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, June 08, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.  ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Ga...

11 months ago - GlobeNewsWire

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a company in the clinical stage of immuno-oncology, is dedicated to advancing its ...

11 months ago - GlobeNewsWire

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platfo...

11 months ago - GlobeNewsWire

LAVA Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical-stage immuno-oncology company focused on developing its proprietary...

11 months ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

UTRECHT, The Netherlands, and PHILADELPHIA, April 11, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary G...

1 year ago - GlobeNewsWire

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gamm...

1 year ago - GlobeNewsWire

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 16, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gam...

1 year ago - GlobeNewsWire

LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamma...

1 year ago - GlobeNewsWire

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform o...

1 year ago - GlobeNewsWire

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platfo...

1 year ago - GlobeNewsWire

LAVA Therapeutics Announces Appointment of New Directors to the Board

Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board

1 year ago - GlobeNewsWire

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) --  LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamm...

1 year ago - GlobeNewsWire

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts Poster presentation to include initial data from subcutaneous administration and ...

1 year ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gam...

1 year ago - GlobeNewsWire

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamma...

1 year ago - GlobeNewsWire

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.  ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Ga...

1 year ago - GlobeNewsWire

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamma...

1 year ago - GlobeNewsWire